Understanding Parkinson disease: A complex and multifaceted illness

Journal of Neuroscience Nursing

Volumn 47, Issue 6, 2015, Pages 320-326

  Gopalakrishna, Apoorva ^a   Alexander, Sheila A ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

dopamine neuron; levodopa treatment; movement disorders; MPTP Parkinson; Parkinson disease; Parkinson disease treatment; PD genes; substantia nigra

Indexed keywords

LEVODOPA;

BASAL GANGLION; DOPAMINERGIC NERVE CELL; DRUG EFFECTS; GENETICS; HUMAN; NURSE ATTITUDE; PARKINSON DISEASE; PATHOPHYSIOLOGY; PHYSIOLOGY; SUBSTANTIA NIGRA; TREMOR;

BASAL GANGLIA; DOPAMINERGIC NEURONS; HUMANS; LEVODOPA; NURSE'S ROLE; PARKINSON DISEASE; SUBSTANTIA NIGRA; TREMOR;

EID: 84947054137     PISSN: 08880395     EISSN: None     Source Type: Journal    
DOI: 10.1097/JNN.0000000000000162     Document Type: Article

References (24)

1. Ballard, C., Kahn, Z., & Corbett, A. (2011). Treatment of dementia with Lewy bodies and Parkinson's disease dementia. Drugs and Aging, 28(10), 769-777. doi:10.2165/11594110-000000000-00000
2. Bergman, H., & Deuschl, G. (2002). Pathophysiology of Parkinson's disease: From clinical neurology to basic neuroscience and back. Movement Disorders, 17(Suppl. 3), S28-S40.
3. Bolam, J. P., Hanley, J. J., Booth, P. A., & Bevan, M. D. (2000). Synaptic organisation of the basal ganglia. Journal of Anatomy, 196(Pt. 4), 527-542.
4. Caballol, N., Mart, M. J., & Tolosa, E. (2007). Cognitive dysfunction and dementia in Parkinson disease. Movement Disorders, 22(Suppl. 17), S358-S366. doi:10.1002/mds.21677
5. Franco, R., Li, S., Rodriguez-Rocha, H., Burns, M., & Panayiotidis, M. I. (2010). Molecular mechanisms of pesticide-induced neurotoxicity: Relevance to Parkinson's disease. Chemico-Biological Interactions, 188(2), 289-300. doi:10.1016/j.cbi. 2010.06.003
6. Gandhi, P. N., Chen, S. G., & Wilson-Delfosse, A. L. (2009). Leucine-rich repeat kinase 2 (LRRK2): A key player in the pathogenesis of Parkinson's disease. Journal of Neuroscience Research, 87(6), 1283-1295. doi:10.1002/jnr.21949
7. Helie, S., Chakravarthy, S., & Moustafa, A. A. (2013). Exploring the cognitive and motor functions of the basal ganglia: An integrative review of computational cognitive neuroscience models. Frontiers in Computational Neuroscience, 7, 174. doi:10.3389/fncom.2013.00174
8. Herrero, M. T., Barcia, C., & Navarro, J. M. (2002). Functional anatomy of thalamus and basal ganglia. Child's Nervous System, 18(8), 386-404. doi:10.1007/s00381-002-0604-1
9. Hilker, R., Pilatus, U., Eggers, C., Hagenah, J., Roggendorf, J., Baudrexel, S., I Hattingen, E. (2012). The bioenergetic status relates to dopamine neuron loss in familial PD with PINK1 mutations. PLoS One, 7(12), e51308. doi:10.1371/journal.pone.0051308
10. Hristova, A. H., & Koller, W. C. (2000). Early Parkinson's disease: What is the best approach to treatment. Drugs and Aging, 17(3), 165-181.
11. Jankovic, J. (2008). Parkinson's disease: Clinical features and diagnosis. Journal of Neurology, Ne u rosurge ry, a n d P sychiatr y, 79(4), 368-376. doi:10.1136/jnnp.2007.131045
12. Lesage, S., & Brice, A. (2009). Parkinson's disease: From monogenic forms to genetic susceptibility factors. Human Molecular Genetics, 18(R1), R48-R59. doi:10.1093/hmg/ddp012
13. Müller, T. (2013). Pharmacokinetic considerations for the use of levodopa in the treatment of Parkinson disease: Focus on levodopa/carbidopa/entacapone for treatment of levodopa-associated motor complications. Clinical Neuropharmacology, 36(3), 84-91. doi:10.1097/WNF.0b013e31828f3385
14. National Parkinson Foundation. (2014). Parkinson's disease overview. Retrieved from http://www.parkinson.org/parkinsons-disease.aspx
15. Nuytemans, K., Theuns, J., Cruts, M., & Van Broeckhoven, C. (2010). Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: A mutation update. Human Mutation, 31(7), 763-780. doi:10.1002/humu.21277
16. Parkinson's Disease Foundation. (2014). Statistics on Parkinson's. Retrieved from http://www.pdf.org/en/parkinson-statistics
17. Post, B., van der Eijk, M., Munneke, M., & Bloem, B. R. (2011). Multidisciplinary care for Parkinson's disease: Not if, but how! Practical Neurology, 11 (2), 58-61. doi:10.1136/pgmj.2011.241604rep
18. Recchia, A., Debetto, P., Negro, A., Guidolin, D., Skaper, S. D., & Giusti, P. (2004). Alpha-synuclein and Parkinson's disease. FASEB Journal, 18(6), 617-626. doi:10.1096/fj.03-0338rev
19. Rodriguez-Oroz, M. C., Jahanshahi, M., Krack, P., Litvan, I., Macias, R., Bezard, E., & Obeso, J. A. (2009). Initial clinical manifestations of Parkinson's disease: Features and pathophysiological mechanisms. Lancet Neurology, 8(12), 1128-1139. doi:10.1016/s1474-4422(09)70293-5
20. Schulz-Schaeffer, W. J. (2010). The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia. Acta Neuropathologica, 120(2), 131-143. doi:10.1007/s00401-010-0711-0
21. Smeyne, R. J., & Jackson-Lewis, V. (2005). The MPTP model of Parkinson's disease. Brain Research, Molecular Brain Research, 134(1), 57-66. doi:10.1016/j.molbrainres.2004. 09.017
22. Smith, W. W., Pei, Z., Jiang, H., Moore, D. J., Liang, Y., West, A. B., I Ross, C. A. (2005). Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proceedings of the National Academy of Sciences of the United States of America, 102(51), 18676-18681. doi:10.1073/pnas.0508052102
23. Tan, E. K., & Skipper, L. M. (2007). Pathogenic mutations in Parkinson disease. Human Mutation, 28(7), 641-653. doi:10. 1002/humu.20507
24. Williams-Gray, C. H., Foltynie, T., Lewis, S. J., & Barker, R. A. (2006). Cognitive deficits and psychosis in Parkinson's disease: A review of pathophysiology and therapeutic options. CNS Drugs, 20(6), 477-505.